Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page
- Check7 days agoChange DetectedAdded related topics links for Lung cancer and MedlinePlus Genetics to the page; these expand available health-information resources without altering study details.SummaryDifference0.2%

- Check14 days agoChange DetectedThe recruitment status is updated to closed, and new guidance links were added to help users read the study record and join a study. Minor UI/content updates include a header label adjustment (Intervention/Treatment), a revision tag, and removal of some related-topic terms.SummaryDifference0.6%

- Check21 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a minor metadata update. No study data or visible content appears to be affected.SummaryDifference0.1%

- Check28 days agoChange DetectedThe related topics header and its entries (Lung cancer and MedlinePlus Genetics) were removed, reducing quick links to disease-related resources on the page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page shows a revision update from v3.5.3 to v3.5.4, signaling a deployment/build update. No study content or parameters appear to be modified.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision: v3.5.3 has replaced Revision: v3.5.2 as the page version label, indicating a new site release; no study information or visible content appears to be affected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.